Antigen Discovery was awarded a $600,000 Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund a collaborative project focused on developing a handheld, point-of-care microfluidic immunodiagnostics platform for detecting infectious diseases during mass disasters, natural disease outbreaks, or bioterrorist threats. Announcement of the grant comes just a couple of days after Antigen confirmed being awarded $2.5 million by the NIAID to continue its work on the development of Plasmodium parasite biomarkers that indicate response to malaria vaccine candidates in development by Sanaria.
